Cargando…
Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection
INTRODUCTION: Clostridium difficile infection (CDI) is a common cause of nosocomial diarrhea. Metronidazole and vancomycin are the primary treatment options for CDI, but increasing rates of antimicrobial resistance and severe, refractory disease have prompted the need for alternative agents. Tigecyc...
Autores principales: | Britt, Nicholas S., Steed, Molly E., Potter, Emily M., Clough, Lisa A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269622/ https://www.ncbi.nlm.nih.gov/pubmed/25466443 http://dx.doi.org/10.1007/s40121-014-0050-x |
Ejemplares similares
-
Does Adjunctive Tigecycline Improve Outcomes in Severe-Complicated, Nonoperative Clostridium difficile Infection?
por: LaSalvia, Mary T., et al.
Publicado: (2017) -
Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin
por: Lao, Dominador, et al.
Publicado: (2012) -
Intravenous Tigecycline Facilitates Cure of Severe Clostridium difficile Infection (CDI) After Failure of Standard Therapy: A Case Report and Literature Review of Tigecycline Use in CDI
por: Navalkele, Bhagyashri D., et al.
Publicado: (2016) -
Intravenous Immunoglobulin in the Treatment of Severe Clostridium Difficile Colitis
por: Shah, Nihar, et al.
Publicado: (2014) -
Severe community onset healthcare-associated Clostridium difficile infection complicated by carbapenemase producing Klebsiella pneumoniae bloodstream infection
por: Giuliano, Simone, et al.
Publicado: (2014)